GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome
Open Access
- 24 April 2026
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1) , 101
Abstract
Glial fibrillary acidic protein (GFAP) is a significant clinical biomarker of traumatic brain injury (TBI), yet understanding the nature, timing, and impact of its degraded and modified products would inform clinical utility. We report novel GFAP breakdown products (BDPs) and post-translational modifications (PTMs) that are unique to TBI including fragment- and patient-specific citrullination signatures that destabilize GFAP filaments. GFAP and its fragments were sequenced by mass spectrometry (MS) from severe TBI patients’ cerebrospinal fluid (CSF) and sera, identifying two distinct TBI-specific jointly generated product sets within the rod-domain covering coil1 (20–26 kDa) and coil2 (15–19 kDa). Their endings differed from GFAP fragments described in Alzheimer’s and Alexander disease. Label-free quantification showed biofluid co-product abundance differences with coil1-BDPs enriched over coil2-BDPs. Coil imbalance was independently confirmed by immunoblot densitometry in twenty-three TBI patients. Measurements over ten days showed injury day peaks of full-length and end-clipped GFAP fragments, while proteolytic 37/39 kDa and small fragments remained elevated. Six-month outcome (Extended Glasgow Outcome Scale) correlated with GFAP fragments, whereas levels of uncleaved and end-clipped GFAP did not. A human astrocyte culture trauma model provided mechanistic insights linking fluid GFAP levels, subcellular localization, and injury-induced astrocytopathy. A new cleavage site between the two coils was identified through selective epitope loss. Coil1-BDPs were fluid-released post-injury, while coil2-BDPs remained intracellular. Their cellular retention was explained by non-filamentous aggregation of citrulline-modified coil2-BDP’s in pathological astrocytes. Trauma-triggered proteolysis involved calpains and caspases in specific astrocyte injury states using protease inhibitors and live-dye-reporter imaging. These novel data link TBI biofluid GFAP fragments with assembly-defective GFAP aggregation in pathological astrocytes. Clinical TBI outcome correlated with GFAP degradation rather than with overall GFAP release. These translational findings indicate that TBI biomarker GFAP undergoes degradation and modification alongside astrocyte pathology, providing a new conceptual framework for investigating biomarker-associated astrocyte proteinopathy potentially linked to post-traumatic neurodegeneration.Keywords
All Related Versions
Funding Information
- Dana Foundation (“First in man” award # 20182601: “Clinical study and trauma culture model experiments”)
- Dana Foundation (Clinical Neuroscience “First in man” award # 20182601: “Clinical study and trauma culture model experiments”)
- Brain Injury Research Center (BIRC), State of California (“Clinical study and trauma culture model experiments”)
- Brain Injury Research Center (BIRC), State of California (“Clinical study and trauma culture model experiments”)
- National Institute of Health (NIH), Institute of Neuronal Disorders and Stroke (NINDS), Small Business Innovation Research, SBIR (# 1R43NS106972-01 “Validation and GFAP proteoform characterization for assay use”)
- National Institute of Health (NIH), Institute of Neuronal Disorders and Stroke (NINDS), Small Business Innovation Research, SBIR (# 1R43NS106972-01 “Validation and GFAP proteoform characterization for assay use”)
- Abbott Diagnostics (Sponsored Research Agreement: “GFAP fragment analyses”)
- Abbott Diagnostics (Sponsored Research Agreement: “GFAP fragment analyses”)
- BRAINBox Solutions Inc., Richmond VA, USA (Sponsored Research Agreement: “Validation studies and patent licensing”)
- National Institute of Health (NIH), Institute of Neuronal Disorders and Stroke (R01 NS052831 “Biochemical markers of severe traumatic brain injury”)
This publication has 109 references indexed in Scilit:
- Measurement of changes in cerebrospinal fluid pulsation after traumatic brain injury using echo‐planar imaging‐based functional MRINMR in Biomedicine, 2023
- Astrocyte‐mediated mechanisms contribute to traumatic brain injury pathologyWIREs Mechanisms of Disease, 2023
- Functional Recovery, Symptoms, and Quality of Life 1 to 5 Years After Traumatic Brain InjuryJAMA Network Open, 2023
- Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain InjuryJAMA Neurology, 2016
- Mass spectrometric identification of citrullination sites and immunohistochemical detection of citrullinated glial fibrillary acidic protein in Alzheimer's disease brainsJournal of Neuroscience Research, 2015
- Identification and characterization of citrulline‐modified brain proteins by combining HCD and CID fragmentationProteomics, 2013
- An In Vitro Trauma Model to Study Rodent and Human Astrocyte Reactivity2011
- Astrocytes: biology and pathologyActa Neuropathologica, 2009
- Early loss of astrocytes after experimental traumatic brain injuryGlia, 2003
- Optimization by mass spectrometry of a tryptophan‐specific protein cleavage reactionRapid Communications in Mass Spectrometry, 1994